Oncology ESMO26: Lowering toxicity, extending lives, with Syncromune As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.
News ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.
News ESMO26: Tango sees 82% ORR with combo in pancreatic cancer A study of RevMed's Rasonque with Tango's vopimetostat has raised hopes of a new combination therapy for aggressive pancreatic cancer.
News ESMO26: Moderna, MSD reveal cancer jab data early after leak Moderna and MSD shared the results for their melanoma cancer vaccine trial, ahead of a presentation at ESMO tomorrow, after a data breach.
News BMS shakes up R&D under CMO Cristian Massacesi Bristol Myers Squibb is combining its R&D operations into a single unit led by chief medical officer and development head Cristian Massacesi.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.